GENinCode Plc (GENI) Earnings Call Transcripts
GENinCode Plc's Latest Earnings Call - June 10, 2026
GENinCode Plc reported its financial results for the fiscal year ending December 2025, highlighting a 14% revenue growth, which was below expectations due to reduced NHS funding. The company is optimistic about future growth, particularly with the anticipated FDA approval for CARDIO inCode, expected in Q3 2026. Management emphasized the strategic partnership with Thermo Fisher, which is expected to drive significant scale and market penetration in the U.S. and Europe. The company raised $4.7 million in March 2026, extending its cash runway to Q1 2027, and is exploring non-dilutive funding options.
Reported metrics
| Metric | Value |
|---|---|
| Revenue Growth | 14% (miss) |
| Gross Margin | 59% (beat) |
| Cash Position | $0.8 million (neutral) |
| Client Accounts in U.S. | 70 (positive) |
Guidance from management
Management expects to resubmit to the FDA in Q3 2026 for CARDIO inCode approval. They anticipate significant growth following approval and are exploring non-dilutive funding options.
What analysts pressed on
Analysts expressed concerns about the timeline for achieving breakeven, which is contingent on FDA approval and market uptake. Questions also focused on the potential need for additional fundraising and the impact of NHS funding cuts.
Main topics on the call
- NHS Funding Reduction — GENinCode experienced a setback with a reduction in NHS funding, impacting revenue growth. Management is in discussions to restore this funding, which could significantly boost future growth.
- FDA Approval Process — The company is preparing a resubmission to the FDA for CARDIO inCode, addressing previous deficiencies. Approval is expected in Q3 2026, which could be a major growth catalyst.
- Thermo Fisher Partnership — GENinCode completed the first manufacturing phase of CARDIO inCode with Thermo Fisher, aiming for a phased market introduction in the U.S. and Europe. This partnership is crucial for scaling operations.
- U.S. Market Expansion — U.S. sales grew, supported by Medicare and Medicaid reimbursement for CARDIO inCode. The company is expanding its client base, now at 70 accounts, up from 40 at the end of 2025.
Read the full GENinCode Plc transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About GENinCode Plc
GENinCode Plc (GENI) is a publicly listed company in the Health Care Providers and Services industry, within the Health Care sector. It trades on AIM and is based in GB. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 4 calls on record spanning June 4, 2024 to June 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 4 GENinCode Plc earnings call transcripts on record, spanning June 4, 2024 to June 10, 2026. Based on this history, GENinCode Plc reports annually. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- GENI
- Exchange
- AIM
- Country
- GB
- Sector
- Health Care
- Calls on record
- 4
- First call
- June 4, 2024
- Most recent
- June 10, 2026
- Reporting cadence
- annually
| Quarter | Date | |
|---|---|---|
| Earnings Calls | Jun 10, 2026 | Read transcript → |
| Earnings Calls | Oct 2, 2025 | Read transcript → |
| Earnings Calls | Sep 25, 2024 | Read transcript → |
| Earnings Calls | Jun 4, 2024 | Read transcript → |